Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2025-03-24 Share Issue/Capital Cha…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Rejestracja podwyższenia kapitału zakładowego i zmian Statutu Spółki w rejestrze przedsiębiorców Krajowego Rejestru Sądowego
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement from the Management Board ('Zarząd') of Pure Biologics S.A. It details the registration of changes to the company's articles of association following a capital increase through the issuance of new shares ('podwyższenia kapitału zakładowego Spółki w drodze emisji nowych akcji'). The text explicitly mentions the new total share capital, the breakdown by share series (A through N), and the remaining authorized capital. This content directly relates to changes in the company's capital structure and share issuance. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it mentions attaching the consolidated articles of association, the primary focus and substance of the filing is the capital change itself, making CAP more specific than RPA or RNS.
2025-03-24 Polish
Otrzymanie przez Spółkę oświadczenia o przyjęciu oferty objęcia 111.111 akcji serii N - Content (PL)
Share Issue/Capital Change Classification · 99% confidence The document text describes a specific corporate action: the acceptance of an offer to subscribe for 111,111 new Series N shares at a price of 9.00 PLN per share. This action is based on a prior resolution to increase the share capital via a private subscription, excluding pre-emptive rights. This directly relates to changes in the company's capital structure and the issuance of new shares. This aligns best with the 'Share Issue/Capital Change' definition (SHA). It is not a general financing update (CAP) but a specific execution of a share issuance.
2025-03-12 Polish
Otrzymanie przez Spółkę oświadczenia o przyjęciu oferty objęcia 111.111 akcji serii N
Share Issue/Capital Change Classification · 99% confidence The document text, written in Polish, discusses the acceptance of an offer to subscribe for 111,111 new Series N shares at an issue price of PLN 9.00 per share. It explicitly mentions the resolution regarding the increase of the share capital ('podwyższenia kapitału zakładowego Spółki') through the issuance of new shares via private subscription, excluding pre-emptive rights. This action directly relates to changes in the company's capital structure and the issuance of new shares. This aligns best with the 'Share Issue/Capital Change' category (SHA). The document length is short (1081 chars), but it is a direct announcement of a capital change, not just an announcement *about* a report.
2025-03-12 Polish
Treść zawiadomienia z art. 69 Ustawy o Ofercie_Michał Lach
Major Shareholding Notification Classification · 99% confidence The document is titled "Zawiadomienie na podstawie art. 69 ust. 1 lub 2 ustawy o ofercie (wypełnia akcjonariusz)" which translates to a notification based on Article 69 of the Public Offering Act, typically concerning changes in significant shareholdings. The content details the 'Stan posiadania podmiotu' (holding status) before and after an event, specifically mentioning the sale ('Zbycie') of shares by an individual (Michał Lach). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in ownership thresholds. The Polish regulatory context for this type of filing aligns best with the 'Major Shareholding Notification' category (MRQ) in the provided schema, as it reports changes in ownership percentage crossing thresholds.
2025-02-28 Polish
Zawiadomienie o zmianie stanu posiadania akcji Spółki - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document text is very short (575 characters) and explicitly states that the content of a notification received from Mr. Michał Lach regarding a change in shareholding (pursuant to Article 69 of the Public Offering Act) is provided in the attachment to this current report. This structure—announcing receipt of information and referring to an attachment—is characteristic of a regulatory disclosure. Since the content concerns a change in significant share ownership, the most specific category is Major Shareholding Notification (MRQ). However, the text itself is an announcement *about* the notification, not the notification itself, and it uses the generic term 'raport bieżący' (current report). Given the specific nature of the content (change in shareholding), MRQ is the best fit, although RPA or RNS could also be considered if the content was purely administrative. Since the core subject is a change in ownership threshold, MRQ is selected.
2025-02-28 Polish
Osiągnięcie kluczowego kamienia milowego w rozwoju PBA-0405 - pozytywny wynik zakończonego badania fazy 0 z udziałem pacjentów onkologicznych - Content (PL)
Regulatory Filings Classification · 92% confidence The document text discusses the completion of a Phase 0 clinical trial for a novel anti-cancer therapy (PB004/PBA-0405) and reports positive findings regarding the drug's mechanism of action and safety profile in human tissue samples. This type of announcement, detailing significant clinical trial milestones and scientific results, is typically classified as a material event announcement. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific management discussion (MDA), and it relates to the core business development/research, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard regulatory disclosure, or potentially as an 'Investor Presentation' (IP) if it were a presentation, but here it reads like a formal disclosure of results. Given the options, and that it is a specific, material update on R&D progress, RNS serves as the most appropriate general regulatory disclosure category when a more specific R&D/Clinical Trial category is absent. The document length is short (1549 chars), but it contains the core information, not just an announcement that a report is attached, thus it is not RPA.
2025-02-27 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.